Table

Efficacy Endpoints with Secukinumab 150 mg at Week 260 (5 year)

Variable Secukinumab 150 mg1
Total N = 106 Anti–TNF-naïve N = 66 Anti–TNF-IR N = 40
ASAS202 69.9 (83)73.7 (57)61.5 (26)
ASAS402 54.2 (83)63.2 (57)34.6 (26)
ASAS-Partial Remission2 25.3 (83)28.1 (57)19.2 (26)
BASDAI502 53.0 (83)56.1 (57)46.2 (26)
BASMI3 -0.7±1.2 (80)--
BASFI3 -2.8±2.6 (83)--
SF-36 PCS3 8.0±8.5 (79)8.5±8.9 (56)6.8±7.4 (23)
  • Data are reported as observed; 1Includes placebo switchers; 2% responders (n); 3mean change from baseline ± SD (n); IR, inadequate response; N, total number of randomised patients; n, number of evaluable patients; TNF, tumour necrosis factor